Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

10.25

 

EUR

 

-0.97 %

5,440 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
73.63M EUR
Turnover
78K EUR
P/E (adj.) (25e)
21.41
EV/EBIT (adj.) (25e)
22.57
P/B (25e)
13.61
EV/S (25e)
4.9
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
9.00 EUR
Updated
04.03.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 04.03.2025

Latest extensive report

Released: 06.10.2023

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
15.8
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.